

原启生物宣布首关 7000 万美元 C 轮融资，加速实体肿瘤 CAR-T 全球开发进程

中国上海，2026 年 1 月 12 日——全球创新肿瘤免疫疗法领军企业 Oricell Therapeutics Holdings Limited（下称“原启生物”或“Oricell”或“公司”）今日宣布完成 7000 万美元的 C1 轮融资。本轮融资由北京市医药健康产业投资基金、启明创投及一家全球领先的医疗基金领投，QIA（卡塔尔主权基金）、NGS（澳大利亚养老基金）、亦庄国投、骊宸投资、瑞锋资本等机构跟投。

作为细胞治疗药物领域的创新先锋，原启生物始终致力于开发具有全球临床价值的 CAR-T 细胞疗法，并已由多条管线产生了概念验证（POC）性临床数据。Oricell 依托自主创新的 Ori®Ab 抗体筛选与工程平台、Ori®Armoring 结构平台及 OnGo(Fast)CMC 工艺专长，以差异化管线占领全球 CAR-T 技术高地。

原启生物 Ori-C101 是一款靶向 GPC3 用于治疗晚期肝细胞癌（HCC）的自体 CAR-T 药物，已完成一期研究者发起临床研究及注册临床 I 期试验，即将开展关键临床 II 期试验。已读出的临床数据展现出优异的有效性和安全性，并在 ASCO 等国际顶级学术会议上多次发表。该产品有望成为全球首款获批的针对肝细胞癌的 CAR-T 药物。

同时，原启生物的全平台正在诞生多个下一代多靶点多机制的 CAR-T 产品，其创新型分泌型 CAR-T OriC902 在极末线实体瘤患者中取得突破性疗效；公司自主开发的双靶点 in vivo CAR-T 产品已启动探索性临床研究，验证了“现货型 CAR-T”的技术潜力——直接在病人体内生成 CAR-T 细胞，极大地提升了细胞药物的可及性。

此次美元融资将加速原启生物的国际化 and 临床开发进程，夯实其在细胞治疗领域的技术实力，产业化管线价值。

原启生物董事长兼首席执行官杨焕凤博士表示：“非常感谢投资人对公司的认可，公司将持续聚焦核心管线的全球临床推进与 in vivo 产品以及前沿技术研发，发挥公司深厚的技术积累和当前在政策和市场方面的机遇，加快临床阶段产品的开发速度，用更具突破性的细胞治疗方案，为全球肿瘤患者带来新的治愈希望，向成为全球领先的免疫治疗企业稳步迈进。”

北京顺禧私募基金管理有限公司董事长、总经理任鹏先生表示：“我们认为细胞治疗是攻克实体瘤的重要方向，原启生物 GPC3 CAR-T 在治疗肝癌上的临床进展让我们非常惊喜。我们高度认可团队的研发实力与商业化视野，期待本轮融资助力公司加速核心产品的全球临床突破。”

启明创投主管合伙人胡旭波先生表示：“作为原启生物的早期投资方，我们陪伴并见证公司在 CAR-T 领域的深耕与步步进阶：从自体 CAR-T 到分泌型 CAR-T 再到 3 天快速生产工

艺，以及 in vivo CAR-T 的前瞻性布局，我们看到了公司在研发上的持续开拓。我们很高兴能够参与到有潜力产生全球性突破性技术和产品的过程里。”

关于原启生物

原启生物是一家临床阶段的生物技术公司，致力成为创新驱动的全球领先肿瘤免疫疗法开拓者，目前专注开发创新型细胞疗法，以解决全球肿瘤学和免疫学领域未被满足的医疗需求。通过自主创新的 Ori®Ab 抗体筛选和工程平台、Ori®Armoring 结构平台及 OnGo(Fast)CMC 领域积累的专识，原启生物开发了多条治疗实体肿瘤和血液肿瘤的产品管线，并在探索性临床研究中验证出良好的安全性和有效性，相关临床研究数据分别在 2021 ASCO、2022 ASCO、2022 EHA、2024 ASCO、2024 SITC、2024 ASH、2025 AACR、2025 ASCO、2025 EHA 以及《柳叶刀血液学》等国际会议以及国际学术期刊发布。原启生物始终致力于通过创新技术推动细胞治疗领域的发展，为患者带来新的希望。了解更多信息，请访问官网：www.oricell.com。

关于北京市医药健康产业投资基金

北京市医药健康产业投资基金由北京顺禧私募基金管理有限公司（“顺禧基金”）管理。顺禧基金是北京国管旗下全生命周期投资平台，重点聚焦战略性新兴产业投资。自成立以来，顺禧管理公司由定位为北京国管旗下“投早、投小、投科技、投北京”的创投平台逐步成长为全生命周期投资平台，通过与多家高校院所、新型研发机构、市区两级国资基金、市场化合作 GP、产业链主企业、政府主管部门建立良好合作关系，不断打造多维度协同支撑体系，积累了优势独特、渠道多元的优质项目资源和投后赋能能力。

关于启明创投

启明创投成立于 2006 年，先后在上海、北京、苏州、香港（中国）、西雅图、波士顿和旧金山湾区设立办公室。目前，启明创投旗下管理 11 只美元基金，7 只人民币基金，已募管理资产总额达到 94 亿美元。自成立至今，专注于投资科技及消费（Technology and Consumer, T&C）、医疗健康（Healthcare）等行业早期和成长期的优秀企业。

关于亦庄国投

北京亦庄国际投资发展有限公司（下称“亦庄国投”）是一家以促进北京产业发展和科技创新为使命的国有资本投资运营公司。亦庄国投紧紧围绕“专业化、市场化、价值化的产业赋能型投资平台”功能定位，聚焦新一代信息技术、生物技术和大健康、新能源智能汽车、机器人和智能制造四大产业，深耕产业投资、基金管理、科技金融、信创基地四大主业，积极助力北京“四个中心”功能建设。截至 2025 年 9 月底，亦庄国投资产总额超

1400 亿元，在管投资项目超 280 个。在管基金 90 余只，实缴出资超 600 亿元，基金总规模超万亿元。

关于骊宸投资

骊宸投资成立于 2021 年，是一家专注于创新生物医药领域早期投资的专业机构。以满足临床刚性需求为出发点，骊宸投资期望携手拥有独立知识产权及全球领先技术的企业和企业家，与之共同成长，开发出可以实现临床获益的产品及方案，造福于病人和社会。

关于瑞锋资本

瑞锋资本是香港证监会持牌机构财富港湾旗下的私募股权投资机构，专注于大中华地区成长阶段至中型市场阶段的优秀企业。通过聚焦核心板块，秉承以企业质量为核心准则、以支持管理团队为核心赋能的理念，通过资本与战略资源赋能，陪伴企业实现可持续成长与长期价值提升。

Oricell Therapeutics Announces \$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies

SHANGHAI, China, January 12, 2026 – Oricell Therapeutics Holdings Limited (“Oricell” or “the Company”), a global leader in innovative cancer immunotherapy, announced today the closing of a \$70M Series C1 financing.

The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global healthcare fund, with participation from **a sovereign wealth fund**, NGS Super (NGS), E-Town Capital, Elikon Venture, and Talon Capital. Proceeds will accelerate Oricell’s global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization.

Oricell is advancing a differentiated pipeline of CAR-T cell therapies for solid tumors, underpinned by three proprietary platforms developed over the past decade:

- Ori®Ab: antibody discovery and engineering library
- Ori®Armoring: enhancement of T-cell persistence and other crucial functions by TAs (Therapeutic Areas)
- OnGo (Fast) CMC: rapid, scalable and effective manufacturing

Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC). Both a Phase I Investigator-Initiated Trial (IIT) and a Phase I IND study of Ori-C101 are completed. With far-leading-industry efficacy and safety profile, Ori-C101’s clinical data have been featured at major academic conferences such as ASCO 2021 and ASCO 2025. Ori-C101 is entering the registrational pivotal trial and is well positioned to become the world’s first approved CAR-T therapy for HCC.

Beyond Ori-C101, Oricell’s integrated platforms are also yielding multiple next-generation CAR-T products with multi-targets and multi-mechanism designs. The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients. Additionally, the company has initiated an IIT study to evaluate its proprietary dual-targeted in vivo CAR-T.

“We are deeply grateful for the strong vote of confidence from our investors,” said **Dr. Helen Yang, Chairlady and CEO of Oricell Therapeutics**. “Oricell will continue to push forward the global clinical advancement of our pipeline, as well as continuous R&D of in vivo products and new technologies. Leveraging our deep technical expertise, policy

tailwind and expanding market opportunities, we are able to accelerate the development of our CAR-Ts in the clinic at full speed. Our mission is to bring efficacious and affordable cell therapies to cancer patients worldwide with the hope of cure. By doing that, we aim to become a leading global immunotherapy enterprise.”

Mr. Peng Ren, Chairman and General Manager of Beijing Medical and Health Care Industry Investment Fund, noted: “We believe cell therapy is a pivotal frontier in the fight against solid tumors, and we are highly impressed by the clinical progress of Oricell’s GPC3 CAR-T in treating HCC. We strongly value the team’s R&D capabilities and commercial vision, and look forward to supporting the company in accelerating global clinical breakthroughs for its core products.”

“As an early investor in Oricell, we’ve witnessed the Company’s evolution from a promising startup to a technology powerhouse—from advancing autologous CAR-Ts to secreting CAR-Ts, to pioneering a 3-day rapid manufacturing process, and now to exploring in vivo CAR-T in the clinic,” said **Mr. Xubo Hu, Managing Partner of Qiming Venture Partners.** “Oricell’s relentless innovation efforts continue to impress us and we are delighted to back a team that is committed to building truly global and groundbreaking therapies.”

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Built on three proprietary platforms: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo (Fast) CMC (rapid manufacturing) — Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies. Multiple candidates have demonstrated favorable tolerability and meaningful clinical activity in early-phase studies. Data have been featured at leading global conferences and top-tier academic journals, including 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH, 2025 AACR, 2025 ASCO, 2025 EHA and *The Lancet Haematology*. Guided by scientific rigor and patient-centric innovation, Oricell is committed to transforming the future of cell therapy and delivering new hope to patients worldwide. For more information, please visit: www.oricell.com.

About Beijing Medical and Health Care Industry Investment Fund

Beijing Medical and Health Care Industry Investment Fund is managed by Beijing Shunxi Private Fund Management Co., Ltd. (“Shunxi Fund”), a full-lifecycle investment platform under Beijing State-owned Capital Operation and Management Co., Ltd. (BSCOMC). Shunxi Fund focuses on strategic emerging sectors—particularly biopharma and healthcare—and has evolved from its original mandate of “investing early, small, in technology, and in Beijing” into a comprehensive investor across the innovation lifecycle. Through partnerships with top universities, research institutes, municipal/state-owned funds, leading industry players, government agencies, and market-driven GP collaborators, Shunxi has built a multi-dimensional ecosystem that delivers unique deal flow and robust post-investment value creation.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading global venture capital firm managing 11 U.S. dollar-denominated funds and 7 RMB funds with \$9.5 billion in capital committed. The firm has invested in leading technology and healthcare companies across early-stage and growth-stage development, building a portfolio recognized for transformative innovation and scalable impact. Qiming’s consistent investment performance has earned it global recognition as a preferred partner for entrepreneurs, with the firm and its partners consistently ranking among the top 10 venture capital firms worldwide across major industry benchmarks. Its reputation for strategic foresight and execution excellence positions Qiming as a cornerstone of the global venture ecosystem.

About E-Town Capital

E-Town Capital is a leading state-owned investment platform dedicated to advancing Beijing’s economic development through strategic investments in high-growth sectors. The firm focuses on biotechnology and healthcare, next-generation information technology, new energy intelligent vehicles, and robotics, operating across four core business lines: industrial investment, fund management, technology finance, and IT infrastructure innovation.

As of September 2025, E-Town Capital manages over 90 funds with RMB 60 billion in paid-in capital and a total fund size exceeding RMB 1 trillion, supporting 280+ investment projects across Beijing’s innovation ecosystem. Its portfolio drives technological advancement while directly contributing to the city’s strategic economic goals.

About Elikon Venture

Founded in 2021, Elikon Venture is a specialized early-stage venture firm focused exclusively on biomedical innovation. The firm partners with entrepreneurs developing proprietary IP and globally competitive technologies to address unmet clinical needs, accelerating the development of therapeutics that deliver measurable clinical outcomes and improve patient health.

About Talon Capital

Headquartered in Hong Kong, Talon Capital is the private equity investment division of Wealth Harbour Investment & Management Co., Limited, an SFC licensed corporation in Hong Kong. It invests in core sectors including technology, healthcare, business services and consumer in Asia across the company lifecycle primarily from growth to mid-market stage. By adhering to an investment philosophy that places company quality at the center and a founder-to-founder approach at the heart of value creation, Talon Capital partners with outstanding businesses to drive sustainable growth and achieve superior return.